S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in

Amplia Therapeutics Limited (ATX.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.08
52-Week Range N/A
Volume77,249 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.


Overall MarketRank

0.76 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 8003 3650
Year FoundedN/A



Sales & Book Value

Annual Sales$894,155.00
Book ValueA$0.11 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive ATX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Amplia Therapeutics Limited (ATX.AX) (ASX:ATX) Frequently Asked Questions

What stocks does MarketBeat like better than Amplia Therapeutics Limited (ATX.AX)?

Wall Street analysts have given Amplia Therapeutics Limited (ATX.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amplia Therapeutics Limited (ATX.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Amplia Therapeutics Limited (ATX.AX)'s key competitors?

Who are Amplia Therapeutics Limited (ATX.AX)'s key executives?

Amplia Therapeutics Limited (ATX.AX)'s management team includes the following people:
  • Dr. John Lambert B.Sc., BSc (Hons), MRACI, C.Chem., Ph.D., CEO, MD & Director (Age 55, Pay $174.13k)
  • Mr. Jeff Carter, Chief Financial Officer (Age 62, Pay $90.3k)
  • Mr. Andrew John Cooke LLB, FAICS, MAICD, FGIA, FCIS, Company Sec. (Age 60, Pay $76.67k)
  • Dr. Mark Devlin B.Sc., Ph.D., Chief Scientific Officer
  • Dr. Frank Gelder, Founding Scientist
  • Dr. James A. Taylor, Trials Consultant (Age 59)
  • Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR, Trials Consultant (Age 72)
  • Dr. Benjamin Segal, Clinical Consultant
  • Dr. Frederick E. Reno, Toxicology Consultant

What is Amplia Therapeutics Limited (ATX.AX)'s stock symbol?

Amplia Therapeutics Limited (ATX.AX) trades on the ASX under the ticker symbol "ATX."

How big of a company is Amplia Therapeutics Limited (ATX.AX)?

Amplia Therapeutics Limited (ATX.AX) has a market capitalization of $0.00 and generates $894,155.00 in revenue each year.

What is Amplia Therapeutics Limited (ATX.AX)'s official website?

The official website for Amplia Therapeutics Limited (ATX.AX) is www.ampliatx.com.

How can I contact Amplia Therapeutics Limited (ATX.AX)?

The company can be reached via phone at 61 2 8003 3650.

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.